Immunomodulatory Strategies for Huntington's Disease Treatment

Author(s): Gabriela D. Colpo*, Natalia P. Rocha, Erin Fur Stimming, Antonio L. Teixeira

Journal Name: CNS & Neurological Disorders - Drug Targets
Formerly Current Drug Targets - CNS & Neurological Disorders

Volume 16 , Issue 8 , 2017


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background & Objective: Huntington's disease (HD) is an autosomal-dominant, progressive neurodegenerative disease characterized by selective loss of neurons in the striatum and cortex, which leads to progressive motor dysfunction, cognitive decline and behavioral symptoms. HD is caused by a trinucleotide (CAG) repeat expansion in the gene encoding the protein huntingtin. Despite the fact that the HD gene was identified over 20 years ago, there is no effective disease-modifying therapy for HD and only symptomatic therapies are available to date. Recently, new agents and procedures have been investigated for HD and many of them have focused on immunomodulatory and/or anti- inflammatory strategies.

Conclusion: The objective of the current review is to summarize data on the therapeutic strategies to treat HD that are based on immunomodulatory effects.

Keywords: Huntington's disease, inflammation, treatment, symptomatic therapies, disease modifying treatment, stem cells.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 8
Year: 2017
Published on: 19 January, 2018
Page: [936 - 944]
Pages: 9
DOI: 10.2174/1871527316666170613084801
Price: $65

Article Metrics

PDF: 31
HTML: 2